Escalating immunomodulatory therapy of multiple sclerosis

The positive results of several multi-center studies significantly improved the immunomodulatory treatment of multiple sclerosis over the last few yea rs. It was demonstrated that different compounds are capable to reduce the number of relapses and to modulate the progression of disease. To improve t he transition of results obtained in these studies into daily clinical prac tice, a consensus group started to prepare a report on the current treatmen t options for the German-speaking European countries. The aim of this paper is to summarize the current knowledge, compare the results of recent clini cal trials with the experience from other therapeutic options and assess th eir clinical evidence.